Most clinical trials for systemic alopecia areata therapies exclude children under 12, forcing dermatologists to rely on off-label treatments and data borrowed from other pediatric conditions. The primary measure of success, the Severity of Alopecia Tool (SALT) score, only tracks scalp hair loss while ignoring eyebrows, eyelashes, and the broader impact on children and their families.
Trials miss the youngest patients
Pediatric dermatologist Brittany Craiglow at Yale School of Medicine identified the biggest evidence gap for children under 12. Though trials are in progress, current treatment relies on off-label use of Janus kinase inhibitors, which are approved for other conditions in younger kids. Starting treatment early leads to better outcomes, but delays can permanently reduce the chance of hair regrowth.
A 6-year-old with no hair since age 2 may never receive treatment if insurers wait until the child turns 12. The same medication would likely be approved for juvenile arthritis. Craiglow noted that childhood is a critical period for self-esteem. Children as young as 3 or 4 begin forming their self-image, and she has heard 4-year-olds ask their mothers, “Am I ugly?” after a classmate’s comment.
These experiences influence how children see themselves and the world. Even if a child didn’t care about their hair—which they do—society still treats them differently.
SALT scores don’t tell the full story
The SALT score offers an objective measure of scalp hair loss but fails to capture what patients value most. Eyebrow and eyelash loss can have a deep effect on how individuals interact with others and perceive themselves. Some patients with mild scalp hair loss struggle more with missing eyebrows or eyelashes than with the condition itself.
Quality of life isn’t reflected in trial results. While it may seem subjective, it remains the most important factor.
Related: User Blocked After Policy Violation
Craiglow observed that children with both atopic dermatitis and alopecia areata often prioritize treating their hair loss over their skin.
Insurers call it “cosmetic”—doctors call it invalidating
Craiglow’s biggest frustration arises when insurers deny coverage, labeling alopecia areata as “cosmetic.” The condition is an autoimmune disease, driven by T-cell activity, and treatments target its root cause. The term “cosmetic” suggests an attempt to enhance appearance, but these children aren’t seeking to look like models—they just want to feel normal.
She compared it to other dermatologic conditions like atopic dermatitis, where treatments are routinely approved.
For families, insurance denials feel like a rejection of their child’s suffering. The refusal isn’t just about hair—it affects how the world perceives them, how they see themselves, and their future. Craiglow argued that managed care must recognize alopecia areata as a medical condition, not a cosmetic issue. If effective therapies exist, insurers shouldn’t decide who gets to live without stigma.
Recent studies have explored markers for tumor response in related autoimmune conditions, offering potential insights for alopecia areata treatment approaches.
